Identification, Characterization and Therapeutic Targeting of Key Molecular Markers and Pathways Implicated in the Development of Hemophilic Arthropathy
Dr. Esther Cooke received her Ph.D. from the Leeds Institute of Cardiovascular and Metabolic Medicine at the University of Leeds, U.K., where she studied the role of fibrinogen phosphorylation in thrombosis. Dr. Cooke is currently a postdoctoral…
Slowdown of Gene Therapy Research Spurs Call to Action
The National Bleeding Disorders Foundation (NBDF) has joined with three international bleeding disorders organizations in their call to action to continue research and development into gene therapy as a treatment option for hemophilia.The joint…
New Article Describes Hemophilia Gene Editing Lexicon
Novel gene editing therapies being developed for hemophilia could represent a significant advance in treatment, should they reach commercialization and become available to patients. They encompass very complex concepts and technologies that prompt…
Michele Warner
NEJM Publishes Follow-up Data on Hemophilia B Gene Therapy Product
The New England Journal of Medicine (NEJM) recently published long-term follow up data on patients who have previously received the hemophilia B gene therapy fidanacogene elaparvovec. The therapy was approved by the U.S. Food and Drug…
Understanding HYMPAVZI™ (marstacimab-hncq)
If you would like to learn more about HYMPAVI (marstacimab-hncq), Pfizer’s new therapy for the treatment of hemophilia, this webinar will give you further insights. This webinar will cover some high-level information on what HYMPAVZI is and how it…
A New Era in Menstrual Care: The Revolutionary Science of Wearable Neurostimulation
Learn more about the clinical trial work and exciting results that demonstrate the potential of wearable neurostimulation to address heavy menstrual bleeding and painful periods. Be among the first to learn about this innovative technology and the…
FDA Grants Jivi Expanded FDA Indication for Younger Hemophilia A Patients
Bayer recently announced that the company’s hemophilia A therapy Jivi® has been granted an expanded indication from the U.S. Food and Drug Administration (FDA). Jivi is a long-acting site-specifically PEGylated recombinant factor VIII therapy that…
LEE Research Advisory Council
LEE DefinitionLived Experience Experts (LEEs) are people living with an inheritable bleeding disorder, as well as their caregivers and family members who are directly impacted by the condition. Their diverse backgrounds and…
coreVWD and the Future of VWD Clinical Trials: Centering the Patient Voice
The coreVWD Initiative brought together a multi-stakeholder group to agree on a list of the most important outcomes to be recommended for inclusion in clinical trials. Join us for an informative and engaging webinar to review the core outcome set…